SERIES: Biomedical Innovation | Number 1 of 3 Next »

Sep 26

Past Event

Conference on Clinical Cancer Research

Video

Highlights

  • Mark McClellan

    McClellan speaks to the necessity of bringing together a variety of voices on the issue of research models and innovative cancer treatments.

    Mark B. McClellan

  • Dr. John Niederhuber

    Dr. Niederhuber links the collaborative clinical research efforts between the private and public sectors to advancements in cancer research and treatment.

    Mark B. McClellan

Summary

Consensus among stakeholders is needed to find solutions to critical questions regarding the future of clinical cancer research. Throughout this day-long conference, panelists sought to address this challenge, discussing pressing scientific and regulatory challenges and opportunities for progress in innovations in cancer therapy. The first three panels discussed options for clinical data standards, alternative methods for demonstrating the efficacy of promising therapies, and approaches to the joint development of cancer drugs and diagnostic tests. The final panel explored the vision for the future of FDA – looking at how FDA can guide innovation and respond to the challenges of a quickly advancing field.

Featured panelists included Dr. Mark McClellan, Dr. David Kessler, Dr. Ellen Sigal, Dr. Janet Woodcock, and others representing the industry, advocacy, regulatory, and academic and government research communities. NCI Director Dr. John Niederhuber made opening remarks, and FDA Commissioner Dr. Andrew von Eschenbach delivered a luncheon keynote address.

The event was convened by the Engelberg Center for Health Care Reform at Brookings in conjunction with the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and Friends of Cancer Research hosted the Conference on Clinical Cancer Research.

Meeting Materials:

Event Summary »

Panel 1 Issue Brief »
Panel 2 Issue Brief »
Panel 3 Issue Brief » 

Slide Presentations »

Event Agenda

  • Welcome and Introductions

  • Panel 1: Data Submission Standards and Evidence Requirements

    • Moderator: Richard Schilsky, MD

      University of Chicago Medical Center

    • Jeffrey Abrams, MD

      National Cancer Institute

    • Gwen Fyfe, MD

      Genentech

    • Robert Erwin

      Marti Nelson Cancer Foundation

    • Janet Woodcock, MD

      FDA

  • Panel 2: Improved Insights into Effects of Cancer Therapies

    • Moderator: Raymond DuBois, MD

      M.D. Anderson Cancer Center

    • Jim Doroshow, MD, FACP

      National Cancer Institute

    • Debasish Roychowdhury, MD

      GlaxoSmithKline

    • Richard Pazdur, MD

      FDA

    • Donald Berry, PhD

      M.D. Anderson Cancer Center

    • Nancy Roach

      C3: Colorectal Cancer Coalition

  • Luncheon Keynote

    • Andrew C. von Eschenbach, MD

      FDA Commissioner

  • Panel 3: Co-Development of Diagnostics & Therapeutics

    • Moderator: Daniel Hayes, MD

      University of Michigan

    • Raymond Woosley, MD, PhD

      Critical Path Institute

    • Steven Gutman, MD

      FDA

    • Richard Simon, DSc

      National Cancer Institute

    • Richard Frank, MD, PhD

      GE Healthcare

    • Nancy Roach

      C3: Colorectal Cancer Coalition

  • Panel 4: Vision for the Future of FDA

    • Moderator: Robert Young, MD

      Fox Chase Cancer Center

    • mmclellanimage

      Mark B. McClellan

      Director, Health Care Innovation and Value Initiative

      Senior Fellow, Economic Studies

    • Anna Barker, PhD

      National Cancer Institute

    • David Kessler, MD

      Former FDA Commissioner

    • David Epstein, MD

      Novartis

    • Ellen Sigal, PhD

      Friends of Cancer Research

  • Final Questions & Closing Comments

Details

September 26, 2008

9:00 AM - 4:30 PM EDT

The Hotel Palomar

Phillips Room

2121 P Street, NW

Map

For More Information

Brynn Barnett

(202) 797-6140

SERIES: Biomedical Innovation | Number 1